

Docket No. 217925US0X PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Toshio OTA, et al.

SERIAL NO: New US PCT application based on PCT/JP00/04515

GAU:

FILED: Herewith

EXAMINER:

FOR: AMYLOID-BETA PROTEIN AGGREGATION-REGULATING FACTORS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION


- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

  
Norman F. Oblon

Registration No. 24,618



22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 10/01)

Surinder Sachar

Registration No. 34,423

James D. Hamilton  
Registration No. 28,421

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO.  217925US0X PCT		SERIAL NO. New US PCT application based on PCT/JP00/04515		
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT  Toshio OTA, et al.				
				FILING DATE  Herewith		GROUP		
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
	AA							
	AB							
	AC							
	AD							
	AE							
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES                  NO			
	AF	98/21328	05/22/96	WO			No	
	AG	99/55865	11/04/99	WO			No	
	AH	979870	02/16/00	EP			No	
	AI							
	AJ							
	AK							
	AL							
	AM							
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)								
	AM	B.J. GAVIN et al.: "Expression of multiple novel Wnt-1/int-1-related genes during fetal and adult mouse developments" GENES & DEVELOPMENT, vol. 4, no. 12B, pages 2319-2332 , 1990						
	AN	J. GHANTA et al.: "A strategy for designing inhibitors of beta-amyloid toxicity" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 47, pages 29525-29528 , 1996						
	AO	Y. DU et al.: "alpha2-Macroglobulin attenuates beta-amyloid peptide 1-40 fibril formation and associated neurotoxicity of cultured fetal rat" JOURNAL OF NEUROCHEMISTRY, vol. 70, no. 3, pages 1182-1188 1998						
	AP	M.M. PALLITO et al.: "Recognition sequence design for peptidyl modulators of beta-amyloid aggregation and toxicity" BIOCHEMISTRY, vol. 38, No. 12, pages 3570-3578 , 03/99						
	AQ	H. LEVINE III, et al.: "Quantification of -sheet amyloid fibril structures with thioflavin T" METHODS IN ENZYMOLOGY, vol. 309, pages 274-284 , 10/99					<input type="checkbox"/> Additional References sheet(s) attached	
Examiner					Date Considered			
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								